We’re on a mission to transform the way you see the genome, and we want to empower you with the tools you need to change the world. Come to booth #1527 to experience how the Saphyr® optical genome mapping system can help you detect structural variants missed by sequencing methods, and how the Bionano genomic analysis software can help you characterize copy number and structural variants so that you can see more genomic variation that matters.

READY TO LEARN MORE?

Book time with us at AMP, or another time that works for you.

Book Now

 

 

Reveal more genomic variation that matters with the Saphyr system for genome-wide structural variant analysis.
Identify more clinically-relevant variants from sequencing, array, and OGM data with our software solutions.
Access OGM analysis on your research samples or order clinical OGM testing through Bionano Laboratories.

VISIT THE BIONANO BOOTH #1527
To learn more about our solutions.

Together we can transform how you drive discovery – and how you change the world.

CORPORATE WORKSHOPS

Corporate Workshop
Maximizing Detection of Pathogenic Structural Variants Across Hematological Malignancies with Optical Genome Mapping
Wednesday, November 2
9:00 – 9:50 AM
Room 229 AB
Panelists
Alka Chaubey
Alka Chaubey, PhD, FACMG
Chief Medical Officer
Bionano Genomics
Rashmi Kanagal-Shamanna
Rashmi Kanagal-Shamanna, MD
Director, Molecular Diagnostic Lab
MD Anderson Cancer Center
Nikhil Sahajpal, PhD
ABMGG Fellow
Greenwood Genetic Center
Adam Smith
Adam Smith, PhD, FCCMG, FACMG
Director, Cancer Cytogenetic Laboratory and Clinician Investigator
University Health Network, Toronto

In hematological malignancies, the study of structural variants (SVs) is essential for proper characterization of clinical research samples and informing actionable insights. In addition, the World Health Organization recommends assessment of both molecular and cytogenetic abnormalities for proper classification of these tumors. However, conventional cytogenetic tools (karyotyping, FISH, microarrays) used to assess these samples miss many important pathogenic events due to poor resolution or ability to detect certain types of SVs. Optical Genome Mapping (OGM) has emerged as a newer approach that overcomes conventional cytogenetics limitations by enabling unbiased, genome-wide evaluation of all classes of SVs in a single workflow, maximizing pathogenic findings. OGM also detects multiple types and sizes of SVs missed by sequencing technologies. Combining OGM and Next-Generation Sequencing (NGS) has proven to be a powerful solution to detect alterations across the variant continuum – from SNVs and small InDels to all classes and sizes of SVs – in hematological samples. During this workshop, the panelists will review studies with multiple types of hematological malignancies, compare results generated from OGM as compared to traditional cytogenetics, and highlight the benefits of combining OGM with NGS for maximizing actionable results.

Corporate Workshop
Comprehensive Assessment of HRD from Next-Generation Sequencing and Optical Genome Mapping
Wednesday, November 2
10:00 – 10:50 AM
Room 229 AB
Panelists
Alka Chaubey
Alka Chaubey, PhD, FACMG
Chief Medical Officer
Bionano Genomics
Rashmi Kanagal-Shamanna
Rashmi Kanagal-Shamanna, MD
Director, Molecular Diagnostic Lab
MD Anderson Cancer Center
Ravindra Kohle
Ravindra Kolhe, MD, PhD, FCAP
Professor of Pathology and Medical Director
Augusta University
Christopher Lum
Christopher Lum, MD
Medical Director, Molecular Diagnostics
Queen's Medical Center

Homologous recombination deficiency (HRD) is characterized by the inability to accurately repair double strand breaks in DNA via homologous recombination. HRD is highly prevalent in ovarian tumors as well as linked to other tumor types and is being widely explored in clinical research studies. For a proper evaluation and stratification of HRD status, it is recommended to assess mutational status of BRCA1 and BRCA2 genes, as well as measuring three types of genomic scars that occur as a result of HRD: LOH, TAI, and LST.

During this workshop, we will discuss common and innovative methodologies for HRD assessment, such as NGS, microarray and Optical Genome Mapping, and bioinformatics approaches for analysis of data, across solid tumors and hematological malignancies. Case studies and results will be overviewed across three presentations provided by speakers from leading institutions

Networking Event

OGM Curious

HAVE A BALL AT OUR NETWORKING SOCIAL.

Join Bionano at for dinner, drinks, and bowling while you network with colleagues. While throwing strikes in stylish shoes, learn more about our partnership with Ignite Worldwide, a nonprofit that introduces over 80,000 girls and non-binary youth to STEM education and career development each year. Post a pic wearing your STEMinist tee on social media and we’ll donate $50 on your behalf to Ignite Worldwide!

Save Me a Lane!

FEATURED SCIENTIFIC SESSION

WHAT’S NEXT FOR CYTOGENOMICS?

Join leading experts as they discuss what next-generation cytogenomics can look like with new tools, including OGM.

Dr. Yassmine Akkari
Nationwide Children’s Hospital
Portland
Dr. Eric Duncavage
Washington University School of Medicine
St. Louis
Dr. Robert Hasser
Massachusetts General Hospital
Boston
Dr. Adam Smith
University Health Network
Toronto
Plenary Session
Next Generation Cytogenomics
Friday, November 4
3:45 – 5:15 PM
Check Program for Location

Poster

Even-Numbered Posters: Friday, November 4 | 9:15 AM – 10:15 AMOdd-Numbered Posters: Saturday, November 5 | 9:15 AM – 10:15 AM
TitleLead Author/Affliliation
Are we using the right tools to calculate homologous recombination deficiency (HRD) scores?Kolhe Lab
Augusta University
Compound heterozygous events in myeloid tumors: Next-generation approach with optical genome mapping and a 523-gene NGS panel
Mosaic structural variation detection with optical genome mapping: Lower limit of detection study
Bringing a new technology in CLIA laboratory: Our experience of clinical validation, getting AMA PLA code, and the Moldx Z-code for optical genome mapping for evaluation of hematological neoplasms
Going beyond karyotyping and FISH: Impact of optical genome mapping (OGM) with additional clinically relevant information in 75 hematological malignancy cases
Optical genome mapping: a potential tier I test for prenatal diagnostic testing
Clinical validation of optical genome mapping for postnatal application
Retrospective optical genome mapping analysis of FSHD1 and 2 negative patients with diminished methylation revealed exon deletions of SMCHD1Stence Lab
University of Iowa
NGS copy number signatures in the assessment of cancers of unknown origin: Targeting therapyLum Lab
Queens Medical Center
Higher resolution and accurate breakpoint determination of a balanced translocation by optical genome mappingMoises Serrano
Bionano Laboratories
Optical genome mapping workflow for somatic abnormality detection in multiple solid tumor typesJames Yu
Bionano Genomics

Stay Connected

Watch our social channels for more updates before, during, and after the event!

Contact Us

Top

This website stores cookies on your computer. These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Privacy Policy.